The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is:
• Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris.
Participants will:
* Take DHA every day for 3 months
* Visit the clinic once every month for checkups and tests
Eligibility
Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria:
* Clinically diagnosed with acne vulgaris;
* For female patients, no pregnancy plans within the next 6 months.
Exclusion Criteria:
* Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
* Patients who have used topical medications for acne within the past 2 weeks;
* Pregnant or breastfeeding women;
* Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Primary outcome measure(s)
Improvement of acne severity by Investigator's Global Assessment (IGA) — Before and immediately after 90-day treatment Improvement of acne severity is considered clinically significant if a subject's IGA improves by at least one grade
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.